$LTRN

Lantern Pharma (LTRN) received a notice from Nasdaq on September 25, 2026, for failing to meet listing rules due to its market value of listed securities being below $35 million for 30 consecutive business days. The company has until March 24, 2027, to regain compliance by achieving a market value of at least $35 million for 10 consecutive business days. Failure to comply may result in delisting from the Nasdaq Capital Market.

Lantern Pharma Inc. (LTRN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering $4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of the warrants DALLAS, TEXAS — (BUSINESS WIRE) — September 29, 2026 – Lan

Lantern Pharma (LTRN) received a USPTO Notice of Allowance for LP-284, extending patent protection to 2042 for treating mantle cell lymphoma and double-hit lymphoma. The patent covers LP-284 as a monotherapy and in combination with other anti-cancer agents. LP-284 is in a Phase 1 clinical trial and has three FDA Orphan Drug Designations.

Lantern Pharma (LTRN) reported Q2 2026 earnings with $7.1M net loss, $7.4M cash, and reduced R&D expenses. LP-300 showed 8.9-month median PFS in L858R patients. The company is advancing LP-184 trials and plans to raise capital for Open Medicine AI, a new AI subsidiary. Management highlighted potential partnerships and cost efficiencies.

Lantern Pharma (LTRN) has a cash runway of about 6 months, with $7.4M in cash and a $14M annual burn rate. While its burn rate decreased 21% year-over-year, the company's burn is high relative to its $30M market cap, raising concerns about its ability to fund operations. The company is debt-free but may need to raise cash soon.

Lantern Pharma Inc. (LTRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update Open Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon 21 L858R Lung Cancer with LP-300; EM

Lantern Pharma (NASDAQ: LTRN) said the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent covering patient selection and treatment for ovarian, primary liver, kidney and thyroid cancers using LP-184 (zirdafulven). The allowed claims relate to a three-gene biomarker signature (PTGR1, PTPN14, ASPH). Lantern cited a 45% disease control rate at or above the effective dose in Phase 1a and plans multiple Phase 1b/2 studies in 2026.

New to The Street said its Bloomberg Television sponsored program airs May 30 at 6:30 PM ET, featuring interviews with executives across AI, healthcare, fintech, digital assets and commodities. Among guests: YesSmile.ai (AI for dental admin in a $200B market), Lantern Pharma (Zeta for rare cancers), Roadzen (AI for auto insurance), and Gold Royalty Corp. (250+ royalties/streams).

RedChip Companies will broadcast interviews with Enlivex Therapeutics (Nasdaq: ENLV) and Lantern Pharma (Nasdaq: LTRN) on its "RedChip Small Stocks, Big Money™" show on Bloomberg TV this Saturday, October 4th, at 7 p.m. ET. The interviews will cover Enlivex's positive Phase IIa results for Allocetra™ in knee osteoarthritis and Lantern Pharma's AI and machine learning platform, RADR®, for cancer drug discovery and development. Both companies will discuss their clinical pipelines and future development plans.

US-based Lantern Pharma Inc., a company focused on AI-driven precision oncology, has announced the opening of an AI Centre of Excellence and Advanced Agentic Labs in Bengaluru, India. This initiative aims to scale up Lantern's AI platform globally, expanding its computational capacity and technical talent. The center will support both Lantern's internal pipeline and collaborations, enhancing its proprietary RADR® AI platform and accelerating the development of specialized large language models and quantitative models for drug discovery.